The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

The present invention discloses a method of purification of prostaglandins including fluorine atoms by using preparative HPLC. Tafluprost and Travoprost are prostaglandins including fluorine. The chemical structure of the impurities in crude Tafluprost and crude Travoprost also contain fluorine, therefore, the removal of the impurities is difficult. Purification by using preparative high performance liquid chromatography (HPLC) can achieve high-quality liquid bulk drugs.

595294 Disclosed herein is a pharmaceutical composition comprising a plurality of sustained release biodegradable microspheres having a diameter between about 30 and about 100 microns, the microspheres comprising from about 10 to about 30 weight percent an anti-hypertensive agent, such as latanoprost, bimatoprost or travoprost, and from about 70 to about 90 weight % a biodegradable polymer, such as a polylactic polyglycolic copolymer (PLGA) and/or a poly lactic acid polymer (PLA), wherein the mi...

The invention relates to a process for the preparation of travoprost of formula (I). comprising that, the compound of formula (II). is stereoselectively reduced, the resulting compound of formula (III) is if desired crystallized, the lactone group of the the compound of formula (III) is reduced, the p-phenyl-benzoyl protecting group of the thus obtained compound of formula (IV) is removed, the resulting triol of formula (V) is, if desired after crystallization, transformed by Wittig reaction int...

The invention relates to a process for the preparation of travoprost of formula(I), comprising that, the compound of formula (II), is stereoselectively reduced, the resulting compound of formula (III), is if desired crystallized, the lactone group of the the compound of formula (III) is reduced, the p-phenyl-benzoyl protecting group of the thus obtained compound of formula (IV), is removed, the resulting triol of formula (V), is, if desired after crystallization, transformed by Wittig reaction i...

The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.

The present invention is related to the formulation of an ophthalmic solution based on two molecules of prostagalndins or prostanoids (Iatanoprost, bimatoprost, travoprost, tafluprost) and an amino acid

PROBLEM TO BE SOLVED: To provide an important alternative to the use of formulations containing polyethoxylated castor oils, such as for use in ophthalmic medicaments, particularly for individuals who are sensitive to the currently available prescription medications.